Pauci-immune necrotizing and crescentic GN accounts for 60% to 80% of all cases of rapidly progressive GN. The histopathology is characterized by small-vessel fibrinoid necrosis, crescent formation affecting variable proportions of glomerular capillaries, little or no glomerular hypercellularity, and little or no deposition of immune complexes in the glomerular capillaries or interstitial arteriolar vessel walls. This pathology is most often attributed to a systemic, small-vessel, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), as defined by the presence of circulating antineutrophil cytoplasmic antibodies (i.e., antimyeloperoxidase [anti-MPO] or anti-proteinase 3 [anti-PR3] antibodies). Although subcategorizations predominate (i.e., microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis), patients often present with mixed features. Pauci-immune, ANCA-negative crescentic GN is a related entity, and the literature concerning clinical manifestations, prognosis, and comparative effectiveness of various treatment options is limited in this disorder.

Small-vessel vasculitides commonly present with nonspecific symptoms of fatigue, weight loss, arthralgias, skin rash, changes in urine appearance or urine output, or—less commonly—hemoptysis suggestive of pulmonary-renal syndrome. Despite the well-documented link between AAV and increased incident venous thromboembolism (VTE), VTE is not a common presenting symptom in small-vessel vasculitis. Factors associated with incident VTE in AAV include the presence of PR3-positive ANCA, urinary red blood cell casts, pulmonary hemorrhage, and cardiac involvement. Across all cases of VTE, the overall percentage of unprovoked VTE attributable to vasculitis has not been well described. Epidemiologic studies have not discussed renal-limited vasculitis as an independent etiology of VTE, even in studies of autoimmune disorders. Moreover, the association between vasculitis and VTE has not been described in ANCA-negative vasculitis, likely because pauci-immune,
ANCA-negative GN is poorly understood and generally understudied. In addition, a major limitation in the current literature regarding VTE in renal vasculitis is the lack of a clear pathophysiologic mechanism to explain the association. In this report we discuss a case of rapidly progressive, pauci-immune, ANCA-negative crescentic GN following presentation for an unprovoked DVT. We further discuss hypercoagulability in vasculitis, including the prevalence, possible mechanisms underlying its pathophysiology, and treatment challenges.

Case Presentation
A previously healthy 70-year-old woman presented to an outside hospital emergency department with complaints of left lower-extremity edema and pain. Initial Doppler ultrasound of the lower extremities was negative for DVT. Urinalysis showed hematuria and bacteriuria; therefore, the patient was discharged with cephalexin. Six days later, she presented again to the emergency department with worsening left lower extremity edema and was admitted to the hospital. A repeat venous Doppler ultrasound revealed extensive DVT involving the left common femoral vein, profunda femoris vein, superficial femoral vein (proximal and mid), with additional impaired compression but laminar flow seen in the left popliteal vein, posterior tibial vein, and peroneal vein. At the time of admission, a complete blood count showed a hemoglobin count of 12.1 g/dl; metabolic panel demonstrated serum creatinine (SCr) 4.5 mg/dl (baseline of 0.9 to 1.0 mg/dl), and blood urea nitrogen (BUN) 104 mg/dl (Table 1). Blood work obtained 1 month before the initial presentation showed SCr 1.19 mg/dl and BUN 18 mg/dl.

Table 1. Laboratory data

| Variable                                      | 38 d before admission (baseline) | 6 d before admission | Day of admission, other hospital | Reference range, other hospital | Day of admission, this hospital | Reference range, this hospital |
|-----------------------------------------------|----------------------------------|----------------------|----------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Serum Hemoglobin (g/dl)                       | 14.0                             | 13.4                 | 12.1                             | 12.0–15.0                      | 8.8                            | 12.0–16.0                      |
| Hematocrit (%)                                | 41.4                             | 40.2                 | 35.8                             | 36.0–48.0                      | 26.8                           | 37.0–47.0                      |
| White cell count (per mm³)                    | 7800                            | 15,500               | 16,700                           | 4500–10,500                    | 20,200                         | 4800–10,800                    |
| Differential (%)                              |                                  |                      |                                  |                                |                                |                                |
| Neutrophils                                   | 41                               | 69                   | 76                               | 84                             |                                 |                                |
| Lymphocytes                                   | 25                               | 15                   | 6                                | 8                              |                                 |                                |
| Monocytes                                     | 21                               | 13                   | 15                               | 8                              |                                 |                                |
| Eosinophils                                   | 13                               | 2                    | 3                                | 0                              |                                 |                                |
| Basophils                                     | 1                                | 1                    | 1                                | 0                              |                                 |                                |
| Platelet count (per mm³)                      | 241,000                          | 218,000              | 343,000                          | 150,000–400,000                | 394,000                        | 160,000–360,000                |
| Sodium (mmol/l)                               | 141                              | 134                  | 129                              | 135–146                        | 131                            | 135–146                        |
| Potassium (mmol/l)                            | 4.7                              | 4.2                  | 4.5                              | 3.5–5.3                        | 3.6                            | 3.5–6.3                        |
| Urea nitrogen (mg/dl)                         | 18                               | 16                   | 104                              | 8–24                           | 83                             | 8–24                           |
| Creatinine (mg/dl)                            | 1.19                             | 1.06                 | 4.5                              | 0.50–1.10                      | 5.60                           | 0.50–1.50                      |
| Estimated glomerular filtration rate (ml/min per 1.73 m²) | 48                               | 53                   | 9                                | ≥60                            | 7                              | ≥60                            |
| Alanine aminotransferase (U/l)                | 22                               | 15                   | 24                               | 5–50                           | 22                             | 5–50                           |
| Aspartate aminotransferase (U/l)              | 30                               | 17                   | 34                               | 5–40                           | 24                             | 5–40                           |
| Alkaline phosphatase (IU/l)                   | 67                               | 73                   | 130                              | 25–125                         |                                 |                                |
| Protein (g/dl)                                | 7.0                              | 7.0                  | 7.5                              | 6.0–8.3                        | 5.8                            | 6.0–8.3                        |
| Albumin                                       | 4.1                              | 4.0                  | 3.4                              | 3.5–5.0                        | 2.5                            | 3.5–5.0                        |
| Prothrombin time (sec)                        | 13.7                             |                      | 11.8–15.2                        | 8.9–12.1                       |                                 |                                |
| International normalized ratio                | 1.04                             |                      | 0.00–1.49                        | <5.00                          |                                 |                                |
| Partial thromboplastin time (sec)             | 32.5                             |                      | 24.0–37.0                        | ≤30                            |                                 |                                |
| Urine Color                                    | Amber                            | Amber                | Yellow                           |                                 |                                |                                |
| Clarity                                       | Cloudy                           | Cloudy               | Clear                            |                                 |                                |                                |
| Specific gravity                              | 1.016                            | 1.015                | 1.005–1.030                      |                                 |                                |                                |
| pH                                           | 5.0                              | 5.0                  | 5.0–8.0                          |                                 |                                |                                |
| Protein (mg/dl)                               | 30                               | 30                   | Negative                         |                                 |                                |                                |
| White cells per high-power field              | 12                               | 32                   | 0–3                              |                                 |                                |                                |
| Red cells per high-power field                | >182                             | >182                 | 0–3                              |                                 |                                |                                |
| Protein-to-creatinine ratio (random, mg/g)    | 2920                             | 0.63                 | 0–200                            |                                 |                                |                                |

*Twenty-one days after admission to other hospital.
To convert the values for urea nitrogen to millimoles per liter, multiply by 0.357. To convert the values for creatinine to micromoles per liter, multiply by 88.4. To convert the values for glucose to millimoles per liter, multiply by 0.05551.
Reference values are affected by many variables, including the patient population and the laboratory methods used.
Systemic anticoagulation with heparin infusion for management of acute DVT was initiated. Renal function initially improved with administration of i.v. fluids and discontinuation of benazepril (Figure 1). Spot urine studies demonstrated sodium 56 mmol/liter, osmolality 448 mOsms/kg, protein/creatinine ratio of 2920 mg/g creatinine, and >182 red blood cells. Gross hematuria, present after placement of a urinary catheter, resolved early in the hospitalization and the patient had normal urine output. Within 48 hours of transitioning to rivaroxaban for long-term anticoagulation, SCr increased to 3.21 mg/dl, and international normalized ratio (INR) peaked at 4.51; therefore, rivaroxaban was discontinued, and i.v. heparin was restarted (Figure 1). Laboratory studies demonstrated persistent leukocytosis, although the patient remained afebrile, and the clinical examination, with additional workup, was negative for an infectious etiology. Computed tomography (CT) of the chest, abdomen, and pelvis with i.v. contrast was performed, redemonstrating evidence of DVT, bilateral pleural effusions, and no evidence of occult malignancy. Renal biopsy was performed on the 17th day of hospitalization, and the patient was transferred to the tertiary medical center on the 22nd hospital day for further management of acute renal failure.

**Renal Biopsy Findings**

An ultrasound-guided kidney biopsy was performed at the outside hospital on Day 17 of hospitalization (23 days after the initial presentation, 5 days before transfer to the tertiary medical center). Evaluation by light microscopy revealed that 27 of 52 glomeruli were involved with focal necrosis and/or crescent formation (Figure 2a and b); the unaffected portions of the glomeruli appeared normal, with no endocapillary or mesangial hypercellularity. Numerous tubular cross sections showed red cell casts (Figure 2c and d). There was mild edema with a mild lymphoplasmacytic infiltrate (Figure 2b and c). There was only mild interstitial fibrosis supporting the clinical findings of acute rather than chronic renal failure. The arteries showed mild arterial intimal expansion, and arterioles displayed mild hyalinosis; no arteritis was identified. Immunofluorescence staining on frozen tissue was negative for IgG, IgA, and complement C1q deposition in the glomerular, tubular, or interstitial compartment and showed mild-to-moderate IgM and complement C3 deposition within the glomerular mesangium (Figure 2f). Electron microscopy was not performed. Altogether, these findings showed evidence of a pauci-immune necrotizing and crescentic GN.

On the patient’s arrival at the tertiary care center, the patient’s chief complaint was worsening edema in the left lower extremity. Review of systems was negative for fever, cough, hemoptysis, fatigue, weight loss, night sweats, arthralgias, diarrhea, emesis, oral ulcerations, and rash. Past medical history included hypothyroidism; essential hypertension; pure hypercholesterolemia; and mild, intermittent asthma. She had never been treated with hormone-replacement therapy, and there was no history of pregnancy miscarriage.
There was no family history of autoimmune disease, coagulation disorders, DVT, or malignancy. She did not smoke tobacco, drink alcohol, or use illicit drugs.

On physical examination, the patient appeared tired. Her temperature was 97.6°F, pulse 88 beats per minute, blood pressure 147/81, respiratory rate 18, and oxygen saturation 94% while she was breathing ambient air. Weight was 87.8 kg, approximately 13 kg above baseline. The lungs had bibasilar coarse crackles. The left lower extremity demonstrated 3+ pitting edema to the thigh, whereas the right lower extremity demonstrated 2+ pitting edema to the mid-shin. There were no dermatologic findings, and the remainder of the examination was normal.

Laboratory tests obtained for workup of acute renal failure are summarized in Table 2. SCr level peaked at 6.13 mg/dl on the 24th day of admission (30 days from initial presentation). Renal and urinary ultrasound with Doppler studies was negative for renal vein thrombosis, obstruction, and anatomic abnormalities.

### Treatment and Outcome

Considering the diagnosis of small-vessel vasculitis with severe renal involvement, immunosuppressive therapy and plasma exchange were initiated. The patient was treated with pulse-dose i.v. methylprednisolone 500 mg/d for 3 consecutive days, followed by oral prednisone 60 mg daily, along with oral cyclophosphamide 1 mg/kg per day (75 mg daily). In light of severe renal dysfunction, 7 plasma-exchange treatments were prescribed over 14 days. Midway through the plasma-exchange treatment course, the patient underwent 1 session of hemodialysis. After 4 plasma-exchange treatments with albumin, the patient...
received alternating albumin and fresh frozen plasma replacement because of bleeding from her vascular access and labile heparin partial thromboplastin times (PTTs). In this case, the decision to initiate cyclophosphamide therapy was based on guidelines for pauci-immune crescentic GN and previous case reports of ANCA-negative patients, as most clinical trials include patients with detectable ANCA serology at diagnosis.

The patient was discharged on hospital day 39, with SCr level of 1.86 mg/dl. Medications on discharge consisted of a tapering scale of prednisone to discontinuation over 24 weeks, oral cyclophosphamide for 4 to 6 months, with plans to continue maintenance immunosuppression with azathioprine 1.5 mg/kg per day for 24 months. Warfarin was selected for long-term anticoagulation. Three months after discharge, the patient had persistent lymphedema secondary to her DVT. Laboratory analysis showed SCr 1.40 mg/dl and BUN 22 mg/dl; urinalysis demonstrated hematuria (16 to 22 red blood cells), proteinuria (≥300 mg/dl), 31 to 40 white blood cells, and spot urine protein/creatinine ratio of 1151 mg/g creatinine (decreased from a peak of 2920 mg/g).

Discussion

This patient’s initial contact with medical care was motivated by lower extremity discomfort secondary to DVT. Subsequent workup led to the diagnosis of small-vessel vasculitis with negative ANCA serology and severe renal involvement. Clinical management of this patient raised key issues and gaps in the current understanding of ANCA-negative small-vessel vasculitis, which are discussed in the following section.

Antineutrophil Cytoplasmic Antibody Negativity

Some have advocated for the inclusion of ANCA-negative, pauci-immune crescentic GN in the spectrum of AAV, as it is possible that ANCA-negative vasculitis may simply represent a failure of current assay detection techniques. However, there is emerging evidence of a distinct pathophysiology. Several mechanisms for ANCA-negative, crescentic GN have been proposed linking non-ANCA antibodies to increased neutrophil activation in the glomerulus. Although the exact identity of these activating factors is unclear, several known inducers of neutrophil induction (e.g., autoantibodies to human lysosomal-associated membrane protein-2 and antiendothelial cell antibodies) have been implicated. Higher levels of neutrophil degranulation are seen in ANCA-negative, pauci-immune patients with GN compared with ANCA-positive patients, and an increased neutrophil presence in Bowman’s capsule results in more severe glomerular lesions. A competing hypothesis pointing to a defect in the alternative pathway of complement—leading to destructive accumulation of activated complement molecules in the glomerulus—has recently been proposed, although with less clinical correlation.

Finally, macrophage cells that disrupt Bowman’s space in ANCA-associated GN may also play a role in ANCA-negative disease. In summary, the extent to which the pathology in ANCA-negative disease differs from ANCA-positive, crescentic GN remains under investigation, and molecular studies point toward mechanisms with overlapping neutrophil, complement, and macrophage dysregulation.

Superimposed Anticoagulant-Related Nephropathy

Given the temporal relationship between this patient’s worsening renal function, increasing INR, the predominance of red blood cells and red blood cell casts in the renal tubules on renal biopsy, and the administration of rivaroxaban, anticoagulant-related nephropathy was considered as a possible etiologic component of her deteriorating kidney function. Anticoagulant-related nephropathy was first described by Brodksy et al. (2009) in relation to administration of warfarin and has subsequently been redemonstrated with novel oral anticoagulants. It is more common in patients with underlying chronic kidney disease, and renal function can recover after discontinuation of the offending agent. In our case, the patient had no history of chronic kidney disease but had recently developed crescentic GN. Her renal function continued to decline after discontinuation of rivaroxaban, likely due to the ongoing small-vessel vasculitis. Although we attribute the findings of red cell casts to anticoagulation, it is unfortunately not possible to pinpoint the underlying etiology on histopathology and therefore introduces the question of whether they may have been due to the vasculitis. The existing literature on red cell casts in AAV is focused primarily on urine sediment rather than renal histology, which limits our ability to address this question.

Hypercoagulability and the Prevalence of Venous Thromboembolism in Small-Vessel Vasculitis

Given the lack of available literature on pauci-immune, ANCA-negative crescentic GN, we focus our discussion primarily on evidence in AAV. Complications of hypercoagulability, such as DVT or pulmonary embolus, have been noted as extrarenal complications of AAV and are common in active disease. For example, Stassen et al. (2008) describe VTE incidence of 6.7 per 100 patient-years among patients with active AAV and 1.8 per 100 patient-years in patients with AAV in remission, which was significantly higher than the incidence of VTE in the general population of 0.3 per 100 patient-years. Importantly, there was no
statistical difference in the distribution of classic VTE risk factors between patients with AAV who did and did not develop VTE in the follow-up period, and most patients had at least 1 traditional risk factor. Reports of incidence and prevalence of VTE in AAV offer large variations. In a 20-year population-based cohort, the hazard ratio for DVT in AAV was 6.25 (95% confidence interval, 1.16–33.60). Among AAV patients with no underlying coagulopathy or risk factors, VTE incidence was found to be 4.3 per 100 person-years by Weidner et al. (2006), versus 1.47 per 100 person-years described by Kang et al. (2018). Unfortunately, however, the concomitant presence of traditional VTE risk factors or hypercoagulable conditions is not always specified. For example, 1 patient in the Eisenberger et al. (2005) cohort had a pulmonary embolism approximately 3 weeks before development of microscopic polyangiitis, although it is not clear if there was a provoking factor. One of the earliest analyses of VTE in AAV by Merkel and colleagues (2005) described an incidence rate of 7 per 100 patient-years, although classic VTE risk factors were not specifically noted. Nonetheless, the majority of available evidence suggests increased risk of VTE in AAV, regardless of the subcategorization of disease (granulomatosis with polyangiitis, microscopic polyangiitis, etc.) or severity of disease.

Most commonly, the reported embolic events in AAV are not the presenting feature of the disease but rather occur in the months after diagnosis. Similar to our case, exceptions to typical presentations have been previously reported. One report describes a patient presenting with intermittent fevers, night sweats, and abdominal pain who was found to have bilateral renal vein thrombosis and bilateral pulmonary emboli on admission. Serologic workup was positive for antimyeloperoxidase antibodies (MPO), lupus anticoagulant, and anticyclic citrullinated peptide antibodies. Given the positive hypercoagulability workup, the unique contribution of AAV to the embolic events cannot be quantified in this case. This is consistent with the reported 8% prevalence of anticyclic citrullinated peptide antibody and lupus anticoagulant in primary systemic vasculitis.

In contrast to classic AAV, hypercoagulability has not been described as a common feature of ANCA-negative, pauci-immune GN, nor has it been described as the presenting complaint in occult disease. Our patient had no known prothrombotic risk factors such as smoking, recent surgery, hormone-replacement therapy, trauma, malignancy, or immobilization, and she was up to date on her age-appropriate cancer screening. Serologic testing did not reveal an underlying hypercoagulable state, apart from nephrotic range proteinuria and associated hypoalbuminemia. Decreased serum albumin is positively associated with risk of VTE in nephrotic syndrome. The mechanism is presumed multifactorial, including compensatory hepatic overproduction of procoagulants (fibrinogen, factors V and VIII), decreased synthesis of natural anticoagulants (free protein S, antithrombin III), and impaired fibrinolysis, as albumin is a required cofactor for binding plasminogen to fibrin. The triad of hypoalbuminemia, hypercholesterolemia, and elevated fibrinogen in nephrotic syndrome further contribute to increased platelet aggregation and abnormal clot architecture. Although there was likely an element of concomitant anticoagulant-related nephropathy in this case, the improvement in kidney function in response to plasmapheresis therapy strongly suggested an underlying inflammatory process driven by circulating immune factors. Therefore, we conclude that the event of VTE in this case was likely related to the underlying systemic inflammatory process that led to renal decline, as otherwise hypothesized in ANCA-positive small-vessel vasculitis. Despite absence of other clinically apparent end-organ involvement with small-vessel vasculitis, the presence of DVT without other known prothrombotic factors argues for a systemic inflammatory and autoimmune condition rather than renal-limited small-vessel vasculitis.

Pathophysiology of Hypercoagulability in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Thromboembolic disease has also been increasingly recognized as a common complication in other vasculitides. The hierarchy of VTE risk among various autoimmune and vasculitis disorders has been described by several investigators. With the exception of Behçet disease, in which venous thrombosis is the most common vascular manifestations, the incidence of VTE in AAV appears to be higher than in other autoimmune, inflammatory conditions such as systemic lupus erythematosus, rheumatoid arthritis, or polyarteritis nodosa, suggesting a novel pathway. Several mechanisms have been proposed to underlie the pathophysiology of VTE in systemic inflammatory conditions of vasculitis and autoimmune disease. Figure 3 summarizes putative pathways linking inflammation and disordered immune system with development of VTE and the clinical data are summarized in Table 3. The proposed mechanisms, not mutually exclusive, perturb the elements of Virchow’s triad classically used to explain the pathophysiology of VTE: blood flow, endogenous constituents of anti- and prothrombosis, and the vessel wall. Central to the model for the development of
VTE in vasculitis and autoimmune diseases is endothelial cell injury, which triggers a cascade of molecular factors that interconnect the immune and coagulation systems as summarized here.

- **Neutrophils are primed by proinflammatory factors, activated, and interact with endothelial cells.** Proposed priming factors include granulocyte-mediated colony stimulating factor (GM-CSF), 53 complement 5a (C5a), 53,65 and tissue factor (TF). 53 Tissue necrosis factor alpha (TNFα) was initially favored to be a key mediator; 56 however, *ex vivo* experiments using TNFα inhibitors did not result in decreased neutrophil priming. 53,55 In comparison, inhibiting C5a did prevent neutrophil priming and the downstream effects. 53 In AAV, primed neutrophils are thought to be primarily activated by serum ANCA, 56,66 although additional neutrophil activators may also be involved. 21,57,67 The activated neutrophils interact with the endothelial cells with consequent oxidative stress, increased expression of adhesion molecules, and further recruitment of leukocytes and platelets. 55,68 Disruption of the vascular endothelium creates a microenvironment that promotes thrombosis and increases vascular wall permeability. Thrombogenic TF is released from the activated endothelial cells and exposed subendothelial matrix. 69

- **Primed, activated TF-positive neutrophils degranulate and release reactive oxygen species, TF-positive microparticles (MPs), 52,53,55 and TF-positive neutrophil extracellular trap (NET) molecules, 66 which activate the coagulation cascade.** 53,60 A detailed review of NET formation can be found in Laridan *et al.* (2019). 70 Briefly, upon activation, the neutrophils release chromatin and other nuclear, cytoplasmic, and granular proteins in the extracellular space that encompass the NET
| Reference                  | Study description                                                                 | Ex vivo or serologic findings                                                                 | Conclusions                                                                                     |
|----------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Berden et al. (2010)        | Assessment of prevalence and function of anti-plasminogen antibodies in two populations of patients with AAV (UK n = 74; Dutch n = 38) | Anti-plasminogen antibodies present in 25% of both AAV cohorts (vs. 2% in controls). In the UK cohort, 24% of the anti-plasminogen antibodies delayed fibrinolysis (vs. none of the controls), with a mean delay of 5.2 minutes (SD 2.8). | Anti-plasminogen antibodies and anti-IPA antibodies are more prevalent in AAV and can delay fibrinolysis. These antibodies were also associated with higher percentages of fibrinoid necrosis and cellular crescents, as well as worse renal function. |
| Hao et al. (2013)           | Detection of anti-plasminogen antibodies during active disease and remission in patients with AAV (n = 104) | Anti-plasminogen antibodies were detected in 18.3% of patients with AAV (vs. none of controls). Presence of anti-plasminogen antibodies correlated with higher levels of ESR, creatinine, and CRP. Antibody positive patients had higher BVAS. | Presence of circulating anti-plasminogen antibodies is associated with both active systemic and renal disease in patients with AAV. |
| Hilhorst et al. (2013)      | Assessment of the risk of hypercoagulability in patients with AAV in remission and no recent VTE (n = 31) | Endogenous thrombin potential was elevated in patients compared with matched controls (137% vs. 90%). Factor VIII was also elevated (159% vs. 137%), as was tissue factor pathway inhibitor (122% vs. 101%). | Patients with AAV in remission demonstrate elevated hypercoagulability, which may be due to persistent endothelial dysfunction and may partially explain the elevated risk of VTE. |
| Hong et al. (2012)          | Investigation of the role of ANCA and neutrophil microparticles in children with AAV (n = 9) | ANCA stimulate the release of neutrophil microparticles from primed neutrophils. The microparticles increase production and release of ROS, IL-6, IL-8, and thrombin. Patients with AAV had higher levels of circulating microparticles than inactive disease (442 x 10^4/ml vs. 237 x 10^4/ml) or controls. | The interaction of ANCA with primed neutrophils generates a proinflammatory and prothrombotic environment through the release of neutrophil microparticles and their downstream effects. |
| Huang et al. (2016)         | Investigation of the role of C5a priming in the pathway between ANCA stimulation and the generation of microparticles and NETs in patients with AAV (n = 11) | Neutrophils primed with C5a released more TF-positive microparticles and NETs after ANCA activation than those primed with a positive control. The TF-positive NETs can generate thrombin and TAT complexes. | C5a mediates the activation of the coagulation system in AAV via neutrophil activation. |
| Kambas et al. (2012)        | Investigation of the inclusion of TF in NETosis and its role in hypercoagulability in patients with sepsis (n = 8) | Neutrophils release TF to NETs via autophagy. This TF stimulates generation of thrombin and subsequent PAR-1 signaling to activate the coagulation cascade. | Neutrophil derived TF co-localized in NETs may explain the prothrombotic state in sepsis. |
| Kambas et al. (2014)        | Investigation of TF expression and neutrophil dynamics in patients with AAV (n = 17) | Renal biopsies demonstrate TF-positive NETs. Elevated circulating DNA and TF expressing neutrophil microparticles are correlated with disease activity. | Hypercoagulability in AAV may be due to the thrombotic potential of circulating neutrophil microparticles expressing TF and/or the downstream activation of the coagulation cascade. |
| Kessenbrock et al. (2009)   | Assessment of the role of NETs in small-vessel vasculitis (n = 12) | ANCA activate neutrophil nuclei to induce NETosis. Both PR3 and MPO colocalize within the NET. Renal biopsies of small-vessel vasculitis also demonstrate proximity of NET components and IFN to neutrophil infiltrates in pathologic glomeruli. Serum IFN and circulating MPO-DNA are elevated in patients with active disease and absent in controls. | NETosis is present in small-vessel vasculitis and is stimulated by ANCA. NET formation was not observed in healthy controls or controls with multiple sclerosis, suggesting the specific auto-antigenicity of ANCA in small-vessel vasculitis. |
| Kraaij et al. (2018)        | Investigation of NET formation in patients with MPO- and PR3-positive AAV (n = 99) | Increased NET formation is present in both MPO- and PR3-positive patients compared with controls. However, it does not correlate to serum ANCA levels. NETosis is higher in active disease/relapse than remission, infection, or healthy controls. | NETosis is independent of ANCA (either MPO or PR3) but related to disease activity in patients with AAV. |
| Ma et al. (2014)            | Analysis of coagulation profiles in a prospective cohort of patients with AAV (n = 399) | 4% of patients with active disease developed VTE (vs. none in remission). Compared with those in remission, patients with active AAV had higher levels of serum D-dimer (0.8 mg/L [0.4, 1.5] vs. 0.28 mg/L [0.2, 0.55]), fibrin-degradation products (5.6 mg/L [5.0, 10.0] vs. 1.9 mg/L [1.2, 2.8]), and platelets (269 ± 127 x 10^3/L vs. 227 ± 80 x 10^3/L). | Hypercoagulability in active disease states of AAV may be due to abnormal fibrinolysis. |
| Mendoza et al. (2019)       | Prospective cohort analysis of incident VTE, neutrophil tissue factor activity (MPTFo), and anti-plasminogen antibodies in patients with AAV in remission (n = 41) | 29.3% of patients developed VTE during the study period. Patients who developed VTE have higher mean peak MPTFo than controls (14.0 [4.3-36.6] vs. 0 [0-3.5]). MPTFo is associated with VTE during active disease and remission. Anti-plasminogen antibody is associated with VTE during remission (HR 1.17 [1.03-1.33]). VTE risk is increased 4-times for each 1 g/dl decrease in serum albumin (HR 4.4 [1.5-12.0]). | Patients with AAV in remission are at higher risk of VTE, possibly due to elevated MPTFo and increased anti-plasminogen antibodies. Additionally, serum albumin may be a useful biomarker for assessing VTE risk. |
| Nokazawa et al. (2012)      | Case report of fatal, concomitant DVT and pulmonary hemorrhage in a patient with MPA (n = 1) | NETs are present within the thrombus and the glomerular crescents. The NETs within the thrombus are characterized by increased histone-citratilization compared with thrombi from control patients. | NETosis may be contributing to both hypercoagulability and glomerular damage in patients with MPO and other forms of small-vessel vasculitides. |
molecular network. Both MPs and NETs precipitate the development of clots via expression of TF, allowing for platelet, red blood cell, and plasma protein adherence, as well as clot stabilization through thrombin-dependent fibrin formation.\(^5\,\text{3}\) NETs additionally cause direct endothelial damage, which is independently prothrombotic.\(^6\,\text{5},\,\text{6}\) Patients with AAV demonstrate increased coagulation cascade activity via elevated fibrin turnover,\(^5\,\text{6}\) thrombin,\(^5\,\text{9}\) D-dimer,\(^5\,\text{8},\,\text{6}\) thrombin antithrombin complexes,\(^5\,\text{3}\) and fibrin degradation products.\(^5\,\text{8}\) NETs also stimulate increased ANCA production via dendritic cell activation of autoreactive T helper and B cells, which feeds back into neutrophil activation.\(^5\,\text{1},\,\text{7}\)

### Inhibition of Fibrinolysis

Plasminogen has been described as an autoantigen in PR3-positive small-vessel vasculitis, and its interaction with autoantibodies directed toward complementary PR3, a protein encoded by the antisense RNA of the PR3 gene, is able to block conversion to plasmin.\(^7\,\text{3}\) Antiplasminogen antibodies have been detected in up to 26% of patients with MPO-positive and PR3-positive vasculitis, whereas only present in 2% of the control population. Antitissue plasminogen activator (tPA) antibodies were also detected in nearly 20% of patients with AAV and more commonly in patients with coexisting antiplasminogen antibodies. Functional in vitro studies showed that antiplasminogen and anti-tPA antibodies retarded fibrinolysis.\(^4\,\text{9}\) In some studies, circulating antiplasminogen antibodies were associated with systemic and renal disease activity of AAV.\(^4\,\text{9},\,\text{5}\) Although antiplasminogen antibodies are not alone sufficient to cause a thrombotic event, they may contribute to the prothrombotic environment critical to clot formation and propagation.\(^7\,\text{3}\)

The clinical significance of NETs was evaluated by Nakazawa and colleagues (2012), who described a case of MPO-positive vasculitis with diffuse alveolar hemorrhage in which thrombosis of the left common iliac vein was incidentally discovered on imaging.\(^7\,\text{9}\) Autopsy allowed for identification of NETs within the thrombus itself and within the glomerular crescents.\(^5\,\text{6},\,\text{5}\) Furthermore, there was an increased burden of histone-citrullination in the thrombus compared with thrombi from patients with non-AAV VTE,\(^7\,\text{9}\) which is consistent with the description of NETs as a scaffold and stimulus from thrombus formation.\(^7\,\text{1}\)

### Challenges in the Treatment of Hypercoagulability in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

A major challenge in the treatment of small-vessel vasculitis is the potential for exacerbation of hemorrhagic complications (i.e., diffuse alveolar hemorrhage) with treatment of acute VTE secondary to
hypercoagulability. This must be considered in the decision to initiate plasma exchange, as it removes essential clotting factors that regulate the coagulation cascade. Plasma exchange is recommended as an adjunct therapy for patients with severe renal disease or pulmonary hemorrhage, although there is no consensus on the definition of severe renal disease.74–76

Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest 7 treatments of plasma exchange over a period of 14 days, with 60 ml/kg replaced with 5% albumin.12,17 If pulmonary hemorrhage is present, then plasma is preferred for replacement fluid.76 In clinical practice, the choice of replacement fluid in plasma exchange is variable and often depends on the clinical context.77 The theoretical risk of treating small-vessel vasculitis with plasma replacement fluid in a patient with both high risk bleeding and VTE rests on the possibility of extending the existing clot or precipitating a new thrombus following infusion of prothrombotic factors.78,79 The French Vasculitis Study Group noted 10 instances of venous thrombosis following plasma exchange (using unspecified replacement fluid); clinical implications of DVT in the context of plasmapheresis therapy were not discussed.80

The hypothesized benefit of plasma exchange in AAV relies on the removal of pathogenic ANCA, as ANCA are typically IgG antibodies readily eliminated during the exchange.81 In ANCA-negative small-vessel vasculitis, the beneficial effects of plasma exchange have been postulated to be derived from removal of cytokines, complement, and other proinflammatory molecules, as well as human lysosomal-associated membrane protein-2 antibody or other antibodies that are hypothesized to contribute to the disease process.23,75 It has also been suggested that some cases of ANCA-negative GN are misclassified because of poor detection of MPO in standard clinical assays and would therefore benefit from plasma exchange for removal of ANCA.82 Although plasma exchange may benefit patients with less severe renal disease at presentation, it is an invasive and expensive therapy, with insufficient evidence to be more broadly employed.77 Furthermore, although patients receiving plasma exchange demonstrate initial improvement in renal function, studies have not shown consistent long-term effects on outcomes of dialysis-dependent renal failure or mortality.75,77,81,83,84 The highly anticipated Plasma Exchange and Glucocorticoids for Treatment of ANCA-Associated Vasculitis (PEXIVAS) trial publication may help clarify the use of plasma exchange in treating AAV, yet its utility in ANCA-negative small-vessel vasculitis will continue to remain poorly defined.85

Renal biopsy is often needed to diagnose the underlying etiology of acute renal failure and is common for patients with AAV. However, biopsy carries significant risks for those who are coagulopathic owing to the chance of retroperitoneal bleeding, as exemplified by this case.86 Standard practice is to hold anticoagulation before biopsy to minimize bleeding; thus, for patients needing ongoing anticoagulation, transition to heparin infusion is preferred in the peri-biopsy period to minimize time off anticoagulation.86,87 In patients taking warfarin or a factor Xa inhibitor, it is recommended to withhold these agents for at least 72 hours before biopsy, whereas a heparin infusion may be continued until several hours before biopsy.88 Anticoagulation may be resumed as soon as 12 hours post-biopsy, although a period of 48 to 72 hours is preferred, depending on the risk of thrombosis.88 An alternative to percutaneous renal biopsy is transjugular renal biopsy, which was first developed for simultaneous hepatic and renal biopsies in patients with multiorgan dysfunction.89 Although this approach can be considered, transjugular renal biopsies carry the additional risk of contrast-induced nephropathy and higher rates of capsular perforation.86 The high complication rates with a transjugular approach in patients with underlying coagulopathy is similar overall to percutaneous renal biopsy in this patient population.89

Another challenge in this case was the superimposed anticoagulant-related nephropathy. Continuation of anticoagulation was, nevertheless, mandatory in this patient. It is interesting to note that continuation of systemic anticoagulation was eventually possible, without further deterioration of renal function. We suspect that the initiation of treatment for vasculitis mitigated the glomerular pathologic changes, which, in turn, reduced the risk of further progression of anticoagulant-related nephropathy. Even though treatment with vitamin K antagonist warfarin was ultimately elected over direct oral anticoagulant therapy for treatment of acute DVT, there is insufficient literature to suggest differential risk profile for glomerular hematuria between the various pharmacologic options of systemic anticoagulation.90,91 The existing observational data comparing non-vitamin K oral anticoagulants (such as rivaroxaban, dabigatran, and apixaban) and warfarin have substantial methodologic limitations.91,92 Avoiding anticoagulation entirely is possible; using alternatives, such as vena cava filters, may be considered. However, these devices are not routinely used in the absence of an acute proximal DVT with a major contraindication to anticoagulation (i.e., massive bleeding, impending surgery), given the substantial costs, risks (i.e., infection, migration, filter thrombosis), need for a second retrieval procedure, and lack of strong evidence suggesting benefit in either VTE rate
Further prospective evidence is needed to guide treatment of hypercoagulability in patients with known anticoagulant-related nephropathy.

Importantly, the state of hypercoagulability may persist even after clinical remission of AAV and ANCA-negative small-vessel vasculitis. The pathophysiology of sustained hypercoagulability is thought to be due to ongoing endothelial dysfunction secondary to persistently elevated endogenous thrombin potential and factor VIII, as well as antiplasminogen antibodies and microparticle tissue factor activity. This may suggest a benefit of ongoing anticoagulation following disease quiescence. However, just as there is no consensus on the overall immunosuppressive therapy duration for AAV, there is insufficient evidence to dictate the duration of anticoagulation therapy for thromboembolic events in patients with small-vessel vasculitis.

Conclusions

This case describes an unusual presentation of biopsy proven pauci-immune, ANCA-negative crescentic GN. Further delay in the diagnosis of small-vessel vasculitis would have taken place if not for her VTE, which suggests occult small-vessel vasculitis may exist despite profound histopathologic activity. To our knowledge, there are no other examples of VTE as the presenting complaint of pauci-immune, ANCA-negative crescentic GN in the literature. In this case, the hematologic manifestation of vasculitis translated into development of lower extremity DVT, which rendered the disease non-renal limited and of questionable small-vessel designation. The patient’s clinical course highlights the tension in treating concomitant high-risk bleeding and hypercoagulability in renal vasculitis as well as the need for further research to clarify the subtleties in the pathophysiology and treatment of ANCA-negative small-vessel vasculitis.

DISCLOSURE

All the authors declared no competing interests.

REFERENCES

1. Chen M, Kallenberg CGM, Zhao MH. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol. 2009;5:313–318.
2. Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmun Rev. 2014;13:723–729.
3. Miller A, Chan M, Wilk A, Misbah SA, Luqmani RA. An approach to the diagnosis and management of systemic vasculitis. Clin Exp Immunol. 2010;160:143–160.
4. Martinez-Martinez MU, Herrera-van Oostdam DA, Abud-Mendoza C. Diffuse alveolar hemorrhage in autoimmune diseases. Curr Rheumatol Rep. 2017;19:17–22.
5. Emmi G, Silvestri E, Squatrito D, et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J. 2015;13:1–10.
6. Ungprasert P, Koster MJ, Thongprayoon C, Warrington KJ. Risk of venous thromboembolism among patients with vasculitis: a systematic review and meta-analysis. Clin Rheumatol. 2016;35:2741–2747.
7. Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20-year population-based cohort study. Mayo Clin Proc. 2018;93:597–606.
8. Kronbichler A, Leierer J, Shin J II, et al. The association of pulmonary haemorrhage, positive pr3-anca and urinary red blood cell casts with venous thromboembolism in ANCA-associated vasculitis. Arthritis Rheumatol. 2019:0–2.
9. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 suppl):S495–S501.
10. Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379:244–249.
11. Yusuf HR, Hooper WC, Beckman MG, Zhang QC, Tsai J, Ortel TL. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis. 2014;38:306–313.
12. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.
13. Harris AA, Falk RJ, Jennette JC. Crescentic glomerulonephritis with a paucity of glomerular immunoglobulin localization. Am J Kidney Dis. 1998;32:179–184.
14. Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–220.
15. Jones RB, Furuta S, Tervaert JWC, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheumatol Dis. 2015;74:1178–1182.
16. Stone JH, Merkel PA, Speira R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–232.
17. Rovin BH, Caster DJ, Catran DC, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95:281–295.
18. Tateyama K, Kodama S, Kishibe K, Harabuchi Y, Suzuki M. A novel strategy with combined assays for detection of anti-neutrophil cytoplasmic antibody (ANCA) in clinically ANCA-negative granulomatosis with polyangiitis patients. Auris Nasus Larynx. 2017;44:735–741.
19. Seidowsky A, Hoffman M, Ruben-Duval S, et al. Elastase-ANCA-associated idiopathic necrotizing crescentic glomerulonephritis: a report of three cases. Nephrol Dial Transplant. 2007;22:2068–2071.
20. Sharma A, Nada R, Naidu GSRSNK, et al. Pauci-immune glomerulonephritis: does negativity of anti-neutrophilic cytoplasmic antibodies matter? Int J Rheum Dis. 2016;19:74–81.

21. Wang F, Chen M, Zhao M. Neutrophil degranulation in anti-neutrophil cytoplasmic antibody-negative pauci-immune crescentic glomerulonephritis. J Nephrol. 2009;22:491–496.

22. Xing GQ, Chen M, Liu G, Wang SX, Zhao MH. Renal neutrophils infiltration in anti-neutrophil cytoplasmic antibodies-negative pauci-immune crescentic glomerulonephritis. Am J Med Sci. 2010;340:474–480.

23. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy. Kidney Int. 2009;54:1121–1126.

24. Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Guillemin L. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009;68:564–567.

25. Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81:190–195.

26. Collet J-P, Mishal Z,esty C, et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency? Thromb Haemost. 1999;82:1482–1489.

27. Trivedi SH, Giugliano RP, Rovin BH, et al. Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrol Dial Transplant. 2017;32:139–145.

28. Chen A, Lee K, Guan T, He JC, Schlondorff D. Role of CD8+ T cells in crescentic glomerulonephritis. Nephrol Dial Transplant. 2019:1–8.

29. Brodsky SV, Eikelboom J, Hebert LA. Anticoagulant-related nephropathy. J Am Soc Nephrol. 2018;29:2787–2793.

30. Wheeler DS, Giugliano RP, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011;80:181–189.

31. Rhee RL, Davis JC, Ding L, et al. The utility of urinary analysis in determining the risk of renal relapse in ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2018;13:251–257.

32. Wiechert H, Hafezi-Rachti S, Ruprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2006;55:146–149.

33. Stassen PM, Derks RPH, Kallenberg CGM, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis: incidence and risk factors. Rheumatology. 2008;47:530–534.

34. Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol. 2009;21:41–46.

35. Wang F, Chen M, Zhao M. Neutrophil degranulation in anti-neutrophil cytoplasmic antibody-negative pauci-immune crescentic glomerulonephritis. J Nephrol. 2009;22:491–496.

36. Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Guillemin L. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009;68:564–567.

37. Trivedi SH, Giugliano RP, Rovin BH, et al. Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Nephrol Dial Transplant. 2017;32:139–145.

38. Wlodek C, Robson MG. Anti-neutrophil cytoplasmic antibody vasculitis presenting with bilateral renal vein thrombosis. Clin Kidney J. 2012;5:229–231.

39. Rees JD, Lanza S, Marques PV, et al. Prevalence of the antiphospholipid syndrome in primary systemic vasculitis. Ann Rheum Dis. 2006;65:109–111.

40. Mendoza CE, Brant EJ, McDermott ML, et al. Elevated microparticle tissue factor activity differentiates patients with venous thromboembolism in anti-neutrophil cytoplasmic autoantibody vasculitis. Kidney Int Rep. 2019;4:1617–1629.

41. Barbour SJO, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;81:190–195.

42. Kanfer A. Coagulation factors in nephrotic syndrome. Am J Nephrol. 1990;(suppl 1):63–68.

43. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Thromb Haemost. 1994;46:287–296.

44. Collet J-P, Mishal Z,esty C, et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency? Thromb Haemost. 1999;82:1482–1489.

45. Tamaki H, Khasnis A. Venous thromboembolism in systemic autoimmune diseases: A narrative review with emphasis on primary systemic vasculitides. Vasc Med. 2015;20:369–376.

46. Springer J, Villa-Forte A. Thrombosis in vasculitis. Curr Opin Rheumatol. 2013;25:19–25.

47. Gaffo AL. Thrombosis in vasculitis. Best Pract Res Clin Rheumatol. 2013;27:57–67.

48. Allenbach Y, Seror R, Pagnoux C, Teixeira L, GuIlpain P, Guillemin L. High frequency of venous thromboembolic events in Churg–Strauss syndrome, Wegener’s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009;68:564–567.

49. Berden AE, Erasmus DD, Bruijn JA, et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. J Am Soc Nephrol. 2010;21:2169–2179.

50. Hao J, Wang C, Gou SJ, Zhao MH, Chen M. The association between anti-plasminogen antibodies and disease activity in ANCA-associated vasculitis. Rheumatology. 2014;53:300–306.

51. Hilhorst M, Winckers K, Wilde B, Van Oerle R, Ten Cate H, Tervaert JW. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol. 2013;40:2042–2046.

52. Hong Y, Eleftheriou D, Hussain AAK, et al. Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol. 2012;23:49–62.

53. Huang YM, Wang H, Wang C, Chen M, Zhao MH. Promotion of hypercoagulability in antineutrophil cytoplasmic antibody-associated vasculitis by C5a-induced tissue factor-expressing microparticles and neutrophil extracellular traps. Arthritis Rheumatol. (Hoboken, N.J). 2015;67:2780–2790.

54. Kambas K, Mitroulis I, Apostolidou E, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One. 2012;7, e45427.
55. Kambas K, Chrysanthopoulou A, Vassilopoulos D, et al. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. *Ann Rheum Dis*. 2014;73:1854–1863.

56. Kessenbrock K, Krumbholz M, Schonermann U, et al. Netting and fibrinolysis index profile in patients with ANCA-associated vasculitis. *PLoS One*. 2014;9(5):8.

57. Kraaij T, Kamerling SWA, van Dam LS, et al. Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. *Kidney Int*. 2018;94:139–149.

58. Ma TT, Huang YM, Wang C, Zhao MH, Chen M. Coagulation and fibrinolysis in patients with ANCA-associated vasculitis. *PLoS One*. 2014;9(5):8.

59. Nakazawa D, Tomaru U, Yamamoto C, Jodo S, Ishizu A. Abundant neutrophil extracellular traps in thrombus of patient with microscopic polyangitis. *Front Immunol*. 2012;3:1–3.

60. Salmela A, Ekstrand A, Joutsi-Korhonen L, Räisänen-Länsimies E, Lundin I, Lassen A. Activation of endothelium, coagulation and fibrinolysis is enhanced and associates with renal anti-neutrophil cytoplasmic antibody-associated vasculitis. *Nephrol Dial Transplant*. 2015;30:i53–i59.

61. Shida H, Hashimoto N, Kusunoki Y, et al. Anti-neutrophil extracellular trap antibody in a patient with relapse of anti-neutrophil cytoplasmic antibody associated vasculitis. *BMC Med*. 2018;19(1):1–6.

62. Van Montfoort ML, Stephan F, Lauw MN, et al. Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. *Arterioscler Thromb Vasc Biol*. 2013;33:147–151.

63. Reese JM, Joseph RP, Cherrington A, et al. Development of participant-informed text messages to promote physical activity among African American women attending college: a qualitative mixed-methods inquiry. *J Transcult Nurs*. 2017;28:236–242.

64. Rosendaal FR. Causes of venous thrombosis. *Deep Vein Thromb Pulm Embolism*. 2009;14(suppl 1):1–26.

65. Schreiber A, Rousselle A, Becker JU, von Mässenhausen A, Linkermann A, Kettritz R. Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis. *Proc Natl Acad Sci*. 2017;114:E9618–E9625.

66. Cartin-Ceba R, Peikert T, Specks U. Pathogenesis of ANCA-associated vasculitis. *Curr Rheumatol Rep*. 2012;14:481–493.

67. Heeringa P, Rutgers A, Kallenberg CGM. The net effect of ANCA on neutrophil extracellular trap formation. *Kidney Int*. 2018;94:14–16.

68. Söderberg D, Segelmark M. Neutrophil extracellular traps in ANCA-associated vasculitis. *Front Immunol*. 2016;7:1–9.

69. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. *BMC Cardiovasc Disord*. 2015;15:1–11.

70. Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. *Semin Thromb Hemost*. 2019;45:86–93.

71. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. *Proc Natl Acad Sci*. 2010;107:15880–15885.

72. Sangaletti S, Tripodo C, Chiodoni C, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. *Blood*. 2012;120:3007–3018.

73. Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. *J Am Soc Nephrol*. 2008;19:2421–2429.

74. Balogun RA, Abdel-rahman EM. Therapeutic plasma exchange and renal related vasculitis: Therapeutic Apheresis Academy 2010. *J Clin Apher*. 2011;26:291–296.

75. Szpir M. Plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis-A 25-year perspective. *Nephrol Dial Transplant*. 2015;30:114–119.

76. Nguyen TC, Kiss JE, Goldman JR, Cercillo JA. The role of plasmapheresis in critical illness. *Crit Care Clin*. 2012;28:453–468.

77. Walsh M, Catapano F, Szpir M, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. *Am J Kidney Dis*. 2011;57:566–574.

78. de Sousa E, Smith R, Chaudhry A, Willcocks L, Jayne D. Venous thromboembolism with concurrent pulmonary haemorrhage in systemic vasculitis. *Nephrol Dial Transplant*. 2012;27:4357–4361.

79. Henderson SR, Salama AD. Haemorrhage and thrombosis: tackling two sides of a single vasculitic disease. *Nephrol Dial Transplant*. 2012;27:4243–4244.

80. De Luna G, Chauveau D, Aniot J, et al. Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: data from the French Vasculitis Study Group. *J Autoimmun*. 2015;65:49–55.

81. Clark WF, Huang SHS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. *Kidney Int*. 2016;90:974–984.

82. Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. *J Clin Invest*. 2013;123:1773–1783.

83. Solar-Cafaggi D, Atisha-Fregoso Y, Hinojosa-Azaola A. Plasmapheresis therapy in ANCA-associated vasculitides: a single-center retrospective analysis of renal outcome and mortality. *J Clin Apher*. 2016;31:411–418.

84. Walsh M, Casian A, Flossmann O, et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. *Kidney Int*. 2013;84:397–402.

85. Walsh M, Meroian PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of ANCA-associated vasculitis: A randomized controlled trial. *Trials*. 2013;14:1–7.

86. Hogan JJ, Mocanu M, Berns JS. The native kidney biopsy: Update and evidence for best practice. *Clin J Am Soc Nephrol*. 2016;11:354–356.

87. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141(2 suppl):e326S–e350.
88. Luciano RL, Moeckel GW. Update on the native kidney biopsy: core curriculum 2019. *Am J Kidney Dis*. 2019;73:404–415.

89. See TC, Thompson BC, Howie AJ, et al. Transjugular renal biopsy: our experience and technical considerations. *Cardiovasc Intervent Radiol*. 2008;31:906–918.

90. de Aquino Moura KB, Behrens PMP, Pirolli R, et al. Anticoagulant-related nephropathy: systematic review and meta-analysis. *Clin Kidney J*. 2019;12:400–407.

91. Shin JI, Luo S, Alexander GC, et al. Direct oral anticoagulants and risk of acute kidney injury in patients with atrial fibrillation. *J Am Coll Cardiol*. 2018;71:251–252.

92. Chan Y, Yeh Y, Hsieh M, et al. The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: a nationwide cohort study in Taiwan. *Int J Cardiol*. 2018;265:83–89.

93. Wassef A, Lim W, Wu C. Indications, complications and outcomes of inferior vena cava filters: A retrospective study. *Thromb Res*. 2017;153:123–128.

94. Duffett L, Carrier M. Inferior vena cava filters. *J Thromb Haemost*. 2016;15:3–12.

95. Bikdeli B, Chatterjee S, Desai NR, et al. Inferior vena cava filters to prevent pulmonary embolism. *J Am Coll Cardiol*. 2017;70:1587–1597.

96. Salvadori M, Tsalouchos A. Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: open challenges in the remission induction therapy. *World J Nephrol*. 2018;7:71–83.